Abstract:Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease with high morbidity and mortality. Cerebral vasospasm, which develops in 3–12 days after aneurysm rupture, has traditionally been considered the major cause of poor outcome postaSAH. However, clinical trials demonstrated that antivasospastic drugs, such as clazosentan, failed to improve the neurofunctional outcomes of patients with aSAH [1], indicating that a complex etiology is involved in the pathogenesis of delayed ischemic neurological deficits (DINDs). Therefore, further elucidation of the pathogenic mechanisms and development of novel effective drugs is of great importance for aSAH treatment. Recently, extensive research has focused on early brain injury (EBI), which occurs within the first 72 h after aSAH. In addition to mechanical damage, hypoxia, and molecular alterations (e.g., NO pathway dysfunction, oxidative stress), EBI can result from inflammation. Importantly, cerebral edema is a major risk factor for early death and bad outcome following aSAH. Additionally, disruption of blood brain barrier (BBB) and inflammation exacerbates the development of EBI by promoting cerebral edema formation. Matrix metalloproteinase 9 (MMP-9) is involved in the degradation of tight junction proteins and microvascular basal lamina proteins, leading to BBB breakdown and brain edema. Thus, suppressing the inflammatory response and MMP-9 activity is vital for the alleviation of EBI in aSAH. Resveratrol (RVS) (3,4′,5-trihydroxystilbene), a natural polyphenol, exerts protective effects against multiple neurological injuries in animal models such as stroke, traumatic brain injury, and spinal cord injury [2–4]. The beneficial effects of resveratrol in central nervous system injuries are associated with its anti-oxidant, antiinflammatory, and antiapoptotic properties [3]. In particular, the inhibitory action of resveratrol on NF-jB has been demonstrated in experimental diabetic neuropathy [5]. NF-jB inhibition can result in downregulation of MMP-9 expression and suppression of the inflammatory response post-SAH [6]. However, although the antivasospastic effect of resveratrol in experimental SAH has been reported [7], no experimental studies to date have focused on the effect of resveratrol on BBB disruption and inflammation after SAH. In our study, we aimed to evaluate whether resveratrol could improve neurological outcomes through inhibition of the NF-jB-dependent inflammatory/MMP-9 pathway after SAH. In this study, aSAH model was induced using a perforation method in sixty Sprague–Dawley rats. Then, resveratrol (30 mL/kg) or normal saline (30 mL/kg) was administered intraperitoneally immediately and again at 6 h after SAH. We found that resveratrol reduced brain edema and promoted functional recovery by preventing BBB disruption after SAH. Further, postSAH resveratrol treatment inhibited the activation of NF-jB, which leads to the downregulation of MMP-9 expression and inhibition of inflammation, contributing to maintenance of BBB integrity. The BBB is a highly specialized structure of the brain microvascular system, and the integrity of BBB is essential for maintaining cerebral microenvironment homeostasis and neural function. Matrix metalloproteases (MMPs), a family of zinc endopeptidases, can degrade interendothelial tight junction proteins and basal lamina proteins of the BBB. Accumulating evidence has demonstrated that MMP-9 participates in the early BBB disruption and cerebral edema formation after aSAH [8]. Increased activity of NFjB has also been observed in both early and late stages of SAH. In

Astaxanthin Reduces Matrix Metalloproteinase-9 Expression and Activity in the Brain after Experimental Subarachnoid Hemorrhage in Rats

Astaxanthin Offers Neuroprotection and Reduces Neuroinflammation in Experimental Subarachnoid Hemorrhage

Astaxanthin Mitigates Subarachnoid Hemorrhage Injury Primarily by Increasing Sirtuin 1 and Inhibiting the Toll-like Receptor 4 Signaling Pathway.

Astaxanthin ameliorates early brain injury after experimental subarachnoid hemorrhage in rats

Astaxanthin Activates Nuclear Factor Erythroid-Related Factor 2 and the Antioxidant Responsive Element (Nrf2-ARE) Pathway in the Brain after Subarachnoid Hemorrhage in Rats and Attenuates Early Brain Injury

Amelioration of Oxidative Stress and Protection Against Early Brain Injury by Astaxanthin after Experimental Subarachnoid Hemorrhage.

Astaxanthin Alleviates Early Brain Injury Following Subarachnoid Hemorrhage in Rats: Possible Involvement of Akt/Bad Signaling

Angong Niuhuang Wan reduces hemorrhagic transformation and mortality in ischemic stroke rats with delayed thrombolysis: involvement of peroxynitrite-mediated MMP-9 activation

Potential Contribution of Hypoxia-Inducible Factor-1α, Aquaporin-4, and Matrix Metalloproteinase-9 to Blood–Brain Barrier Disruption and Brain Edema after Experimental Subarachnoid Hemorrhage

Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice

Hydrogen Sulfide Attenuates Brain Edema in Early Brain Injury after Subarachnoid Hemorrhage in Rats: Possible Involvement of MMP-9 Induced Blood-Brain Barrier Disruption and AQP4 Expression.

Autophagy Activation is Associated with Neuroprotection Against Apoptosis Via a Mitochondrial Pathway in a Rat Model of Subarachnoid Hemorrhage

Neuroprotective Effects of Magnesium Lithospermate B Against Subarachnoid Hemorrhage in Rats

SIRT1 Activation by Resveratrol Reduces Brain Edema and Neuronal Apoptosis in an Experimental Rat Subarachnoid Hemorrhage Model

Mesencephalic astrocyte-derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt-dependent prosurvival pathway and defending blood-brain barrier integrity.

Resveratrol Attenuates Early Brain Injury after Subarachnoid Hemorrhage Through Inhibition of NF‐κB‐Dependent Inflammatory/MMP‐9 Pathway

Potential Contribution of Matrix Metalloproteinase-9 (Mmp-9) to Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage in Rats.

LPS Pretreatment Provides Neuroprotective Roles in Rats with Subarachnoid Hemorrhage by Downregulating MMP9 and Caspase3 Associated with TLR4 Signaling Activation

Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation

Alantolactone reduced neuron injury via activating PI3K/Akt signaling pathway after subarachnoid hemorrhage in rats

Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats